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Background: Homeodomain interacting protein kinases (HIPKs) function as modulators of cellular stress responses
and regulate cell differentiation, proliferation and apoptosis. The HIPK family includes HIPK1, HIPK2 and HIPK3,
which share a similar domain structure, and the more distantly related HIPK4. Although HIPKs phosphorylate their
substrates on serine or threonine residues, it was recently reported that HIPK2 depends on the autophosphorylation
of a conserved tyrosine in the activation loop to acquire full catalytic activity and correct subcellular localization. In
this study we addressed the question whether tyrosine autophosphorylation in the activation loop has a similar
function in the other members of the HIPK family.
Results: All HIPKs contained phosphotyrosine when expressed in HeLa cells. Catalytically inactive point mutants were
not tyrosine-phosphorylated, indicating that HIPKs are dual-specificity protein kinases that autophosphorylate on tyrosine
residues. HIPK point mutants lacking the conserved tyrosine residue in the activation loop showed reduced catalytic
activity towards peptide and protein substrates. Analysis of these mutants revealed that HIPK1, HIPK2 and HIPK3 but not
HIPK4 are capable of autophosphorylating on other tyrosines. Inhibition of tyrosine phosphatase activity by treatment
with vanadate enhanced global phosphotyrosine content of HIPK1, HIPK2 and HIPK3 but did not affect tyrosine
phosphorylation in the activation loop. Mutation of the activation-loop tyrosines resulted in a redistribution of HIPK1 and
HIPK2 from a speckle-like subnuclear compartment to the cytoplasm, whereas catalytically inactive point mutants
showed the same pattern of cellular distribution as the wild type proteins. In contrast, mutation of the activating tyrosine
did not increase the low percentage of cells with extranuclear HIPK3. HIPK4 was excluded from the nucleus with no
difference between the wild type kinase and the point mutants.
Conclusions: These results show that HIPKs share the mechanism of activation by tyrosine autophosphorylation with
the closely related DYRK family (dual-specificity tyrosine phosphorylation regulated kinase). However, members of the
HIPK family differ regarding the subcellular localization and its dependence on tyrosine autophosphorylation.
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Homeodomain-interacting protein kinases (HIPK1, HIPK2,
HIPK3) were originally identified as proteins that interact
with the homeobox transcription factors NKx-1.2 [1].
HIPK1-3 share about 90% identical amino acids in their
kinase domains and are also related in the architecture
of the noncatalytic regions. These include a smaller N-* Correspondence: wbecker@ukaachen.de
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article, unless otherwise stated.terminal part with a conserved sumoylation site and a
large C-terminal domain that harbours a homeobox-
interaction domain, an autoinhibitory domain, a region
rich in proline, glutamic acid, serine and threonine resi-
dues (PEST), and a C-terminus rich in short repeats of
serines, glutamines and alanines (SQA region, also
known as tyrosine/histidine (YH)-rich region) [1,2].
HIPK4 was later identified by its sequence similarity
with HIPK1, 2 and 3 and is the most divergent member
of the HIPK family [3,4]. HIPK4 is not structurally re-
lated with HIPK1-3 outside the catalytic domain [4].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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is involved in the regulation of various cellular processes
including differentiation, proliferation, apoptosis and
stress response to DNA damage and hypoxia [5,6]. Per-
haps most importantly, HIPK2 promotes apoptosis upon
genotoxic stress by phosphorylating the tumor suppres-
sor protein p53 at Ser46 [7-10]. Obviously, the function
of HIPK2 as a regulator of cellular life and death must
itself be tightly controlled. Accordingly, HIPK2 activity
is regulated by several mechanism including degradative
ubiquitination, caspase-mediated cleavage of an autoin-
hibitory domain, sumoylation, acetylation and phosphor-
ylation [11,12]. Most effects of HIPK2 are mediated by
transcriptional regulation, as HIPK2 can either activate
or repress gene expression by interaction with compo-
nents of the transcription machinery [13-15].
Whereas more and more putative targets of HIPK2 are
being identified [15], enhancing our understanding of its
function in cell death and cell survival, much less is
known about the other members of the HIPK family.
Due to their highly similar primary structures, HIPK1
and HIPK2 are assumed to have at least a certain degree
of redundant activity [16]. Whereas HIPK1/2 double
knockout mice die at embryonic day 12.5, either HIPK1
or HIPK2-deficient mice develop grossly normal but ex-
hibit differences in apoptosis induction and eye develop-
ment [17-20]. Although the cellular functions of HIPK1
are not very well defined, available evidence indicates a
role in the regulation of apoptosis by interaction with nu-
clear proteins [16,21]. HIPK3 has been characterized as a
regulator of the androgen receptor and Runt-related tran-
scription factor 2 (Runx2) [22,23]. Recently, HIPK3−/−
mice were shown to have impaired glucose-induced insu-
lin secretion [24], and HIPK3 has been implicated in the
pathogenesis of human type 2 diabetes [25]. Compared to
HIPK2, HIPK1 and HIPK3 are less well characterized re-
garding their molecular and cellular function, and it is un-
clear to which degree these kinases fulfill redundant or
divergent tasks. Almost nothing is known about HIPK4
except for its capacity to phosphorylate p53 at Ser9 [4].
Consistent with their roles in transcriptional regula-
tion, HIPK1, HIPK2 and HIPK3 are predominantly nu-
clear proteins that are concentrated in subnuclear
structures that appear as a punctate pattern [1,21,22,26].
These speckles are distinct from other subnuclear struc-
tures and were thus designated HIPK domains [9]. Inter-
estingly, the punctate nuclear distribution of HIPK2
depends on a functional SUMO interaction motif that is
also present in HIPK1 and HIPK3 [27]. However, in
some cells HIPK2 is localised diffusely in the nucleus
and also in the cytoplasm [9]. These findings suggest
that the subcellular distribution of HIPK2, and possibly
of HIPK1 and HIPK3, is a regulated process relevant for
the biological function of these proteins. In contrast toHIPK1-3, HIPK4 lacks an apparent nuclear localization
signal and was found to be evenly distributed in the
cytoplasm [4].
Although HIPKs phosphorylate substrates on serine or
threonine residues, HIPK2 has recently been shown to
autophosphorylate at a specific, highly conserved tyro-
sine residue following the Mg2+-binding DFG motif in
the activation loop of the catalytic domain [28,29]. This
tyrosine is not only present in all HIPKs but also in
other kinases of the CMGC group including the MAPK
family, GSK3 and the closely related DYRKs [30]. In the
MAPK family, the corresponding tyrosine belongs to a
Thr-x-Tyr motif. Dual phosphorylation of this motif by
specific upstream kinases serves as a regulatory switch
that controls catalytic activity. In contrast, DYRKs and
GSK3 autophosphorylate the activation loop-tyrosine
already during translation, which induces the constitutive
activity of these kinases [31-34]. Similar to the DYRKs,
tyrosine autophosphorylation of HIPK2 is necessary for
full catalytic activity of the mature kinase [28,29]. We and
others have recently shown that DYRK1A and HIPK2 are
not only capable of co-translationally phosphorylating the
crucial tyrosine in the activation loop, but can also as ma-
ture kinases autophosphorylate on tyrosines outside the
catalytic domain [29,34]. In contrast to DYRKs, tyrosine
phosphorylation of HIPK2 has been reported to be at least
partially under the control of upstream kinases [35,36].
Specifically, HIPK2 has been shown to be phosphorylated
by the tyrosine kinase Src on numerous residues,
including Y361 [36]. Phosphoproteomics screens have
provided ample evidence that the activation loop tyrosine
is also phosphorylated in HIPK1, HIPK3 and HIPK4
(phosphosite.org). However, it is unknown whether these
kinases also autophosphorylate on tyrosine and whether tyro-
sine phosphorylation is functionally important. The present
study aims at a comparative analysis of the role of the
activation loop tyrosine in all members of the HIPK family.
Results and discussion
Tyrosine phosphorylation of HIPKs
DYRK1A and HIPK2 autophosphorylate on a tyrosine
residue in the activation loop that is conserved in all mem-
bers of the HIPK family (Figure 1A-C). To address the
question whether all mammalian HIPKs are phosphory-
lated on tyrosine residues, GFP fusion proteins of HIPK1,
HIPK2, HIPK3 and HIPK4 were immunoprecipitated from
HeLa cells and tyrosine phosphorylation was assessed by
western blot analysis with a phosphotyrosine-specific anti-
body. GFP-DYRK1A was included as a positive control
and GFP served as a negative control. Figure 1D shows
that all HIPK members contain immunodetectable phos-
photyrosine when isolated from HeLa cells.
To further investigate the mechanism of tyrosine
phosphorylation in the HIPK family, we created point
Figure 1 Comparison of HIPK structures and tyrosine phosphorylation. A, Schematic illustration of HIPK1-4. The definition of the domains in
HIPK1-3 was adapted from Kim et al. [26]. Nuclear localisation sequences (NLS) and the tyrosine residue in the activation loop (Y) are indicated. B,
The tree illustrates the sequence identity of the catalytic domains of HIPK1-4 and DYRK1A and panel C shows the alignment of the activation loop
sequences. Tyrosine residues known to be autophosphorylated in HIPK2 and DYRK1A are highlighted (red) [28,29,34]. D, GFP fusion proteins of HIPK1-4
and DYRK1A were immunoprecipitated from transiently transfected HeLa cells. Tyrosine phosphorylation was analysed by immunoblotting with a
phosphotyrosine-specific antibody (pTyr). Total amounts of the recombinant proteins were detected with GFP antibody. The figure is representative of
two experiments.
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activation loop was replaced by phenylalanine to reveal
whether this was the only phosphorylatable tyrosine. In
addition, kinase-deficient mutants were generated by
substituting the catalytic aspartate by asparagine [37].
Guided by our previous analysis of DYRK1A autophos-
phorylation [34], one series of cells was treated withsodium orthovanadate (Na3VO4) to inhibit tyrosine
phosphatases that might conceal tyrosine kinase activity
of mature HIPKs in living cells.
Firstly, this experiment revealed that the majority of
the phosphotyrosine in HIPKs results from autophosphoryl-
ation, since phosphotyrosine signals were absent or weak for
all kinase-defective HIPK mutants (Figure 2A-D). The
Figure 2 Tyrosine phosphorylation of HIPK mutants. HeLa cells
were transiently transfected with the indicated expression constructs
for HIPK1 (A), HIPK2 (B), HIPK3 (C) or HIPK4 (D). Sodium orthovanadate
(Na3VO4) was added to every second sample for 1 h before lysis. GFP
fusion proteins were immunoprecipitated and analysed by
immunodetection with antibodies for pTyr and GFP. The panels are
representative of 2–3 independent experiments.
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may result from either trans-autophosphorylation by en-
dogenous HIPK2 or other tyrosine kinases present in HeLa
cells.
Compared to the respective wild-type proteins, the
kinase-defective mutants HIPK1D315N and HIPK2D324N
showed markedly enhanced electrophoretic mobility
(Figure 2A-B). This difference most likely reflects ex-
tensive autophosphorylation in the wild type proteins
that is absent in the kinase dead mutants. Consistently,
wild type HIPK1 and HIPK2 migrated more slowly thanpredicted from their calculated molecular masses (GFP-
HIPK1, 158 kDa, GFP-HIPK2 155 kDa) (Figure 2A-B).
Interestingly, the Tyr→Phe mutants migrated with similar
electrophoretic mobility as wild type HIPK1 and HIPK2,
and vanadate-treatment did not alter migration of HIPK1
or HIPK2. Thus, the observed upshift is attributable to the
phosphorylation of serine/threonine rather than tyrosine
residues. Indeed, migration of HIPK2 was previously
shown to strongly be retarded by treatment with the in-
hibitor of serine/threonine phosphatases, calyculin A [28].
Secondly, HIPK1Y352F and HIPK2Y361F contained sub-
stantial amounts of phosphotyrosine (Figure 2A-B), indi-
cating that these kinases autophosphorylate not only the
conserved tyrosine in the activation loop. In agreement
with our results, Siepi et al. [29] also detected tyrosine
phosphorylation of GFP-HIPK2Y361F and identified several
phosphorylated tyrosines by mass spectrometry analysis.
In contrast, Saul et al. [28] detected no phosphotyrosine in
a FLAG tagged version of this mutant. This difference
may be due to the use of different phosphotyrosine-
specific antibodies and/or due to the use of different
epitope tags. In a direct comparison, we found that the
basal phosphotyrosine signal was weaker (but detectable)
in FLAG-HIPK2Y361F than in the GFP fusion protein
(Additional file 1: Figure S1). Nevertheless, vanadate treat-
ment induced a marked tyrosine autophosphorylation of
FLAG-HIPK2Y361F.
Treatment with vanadate also revealed that HIPK3Y359F
was capable of autophosphorylating tyrosine(s) other than
Tyr359, although this reaction was counteracted by tyro-
sine phosphatases under basal conditions (Figure 2C). In
contrast, HIPK4Y175F did not show any phosphotyrosine
signal above the background as defined by the catalytically
inactive mutant HIPK4D136N (Figure 2D). This difference
between HIPK4 and HIPK1-3 may either be due to differ-
ent enzymatic properties or to the absence of phosphory-
latable tyrosines in HIPK4. In particular, HIPK4 lacks the
C-terminal tyrosine/histidine-rich domain that harbors 8–
10 potentially phosphorylatable tyrosine residues and is
conserved in HIPK1-3 (see Figure 1A).
The autophosphorylation on tyrosines outside the
catalytic loop suggests that HIPK1-3 may also be able to
phosphorylate tyrosines in exogenous substrates. For
DYRK1A, which also autophosphorylates on multiple ty-
rosines [34], no tyrosine site was identified in extensive
peptide array analyses [38,39]. Presently, there is no evi-
dence that any member of the HIPK/DYRK families has
tyrosine kinase activity towards other proteins.
Vanadate treatment enhanced the tyrosine phosphoryl-
ation of HIPK1, HIPK2 and HIPK3 within 1 h, which is
very unlikely to reflect solely the newly synthesized protein.
To fully exclude this possibility, we performed experiments
in cells that were pretreated with the protein synthesis in-
hibitor cycloheximide. Again, increased phosphotyrosine
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Figure S2). This result corroborates the conclusion that
tyrosine kinase activity of HIPK1, HIPK2 and HIPK3 is not
limited to a transient translational conformation of the
catalytic domain. Also of note, the phosphotyrosine signal
of HIPK4 was not enhanced by vanadate treatment. This
may be due to the lack of tyrosine phosphorylation sites
outside the catalytic domain of HIPK4, if the tyrosine
in the activation loop is not subject to dephosphoryla-
tion by tyrosine phosphatases [30,32]. Similarly, wild
type DYRK1A autophosphorylates on tyrosines outside
the activation loop, whereas a deletion construct com-
prising only the catalytic domain does not [34].Figure 3 Tyrosine phosphorylation in the activation loop of HIPK1, H
for wild type GFP-HIPK fusion proteins or the Tyr→Phe mutants thereof (YF). I
1 h or 2 h. Western blots of total cell lysates were detected with antibodies di
independent of the sequence context (PY99) and a GFP antibody. A, The pTy
mutants. B, Effect of vanadate treatment. The column diagrams show the qua
untransfected control samples was subtracted from the signal intensities obta
vanadate treatment was calculated by normalization to the signal measured iTyrosine phosphorylation in the activation loop
The results shown in Figure 2 were obtained with a gen-
eral phosphotyrosine antibody and do not allow a spe-
cific conclusion on the posttranslational phosphorylation
of the activation loop tyrosine. Therefore we took advan-
tage of a new commercial antibody that is directed
against phosphorylated Tyr361 in HIPK2. Owing to the
sequence similarity of the activation loop (Figure 1C) we
expected this antibody to also detect pTyr352 in HIPK1
and pTyr359 in HIPK3. By using the respective Phe→Tyr
mutants, we confirmed that the antibody was indeed
specific for the activation loop tyrosine of these kinases
(Figure 3A). Analysis of HIPK phosphorylation in vanadate-IPK2 and HIPK3. HeLa cells were transfected with expression plasmids
f indicated, cells were treated with sodium orthovanadate (Na3VO4) for
rected against pTyr361 in HIPK2, a general antibody for phosphotyrosine
r361(HIPK2) antibody detects wild type HIPK1-3 but not the Tyr→Phe
ntitative evaluation of 3 experiments. The background signal in the
ined with the phosphospecific antibodies. Relative phosphorylation after
n untreated cells. Means + SEM, * p < 0.05, analysed by one-sample t test.
Figure 4 Maximal activity of HIPKs depends on the activation
loop tyrosine. Wild type GFP-HIPK fusion proteins and the respective
Tyr→Phe mutants were immunoprecipitated from HeLa cells and
subjected to kinase assays with recombinant GST-p27Kip1 (A), myelin
basic protein (B) or DYRKtide (C). GFP served as background control. A,
Phosphorylation of p27Kip1 at Ser10 was detected by immunoblotting
with a phosphorylation-specific antibody. For quantitative evaluation,
pSer10 immunoreactivity was normalised to GFP immunoreactivity,
which reflects the amount of kinase in the reaction. The blots
illustrate a representative experiment, and the relative catalytic
activities as determined from 3–4 assays are shown below the
panels (means ± SD). One-sample t test: *, p < 0.05; **, p < 0.01. B
and C, Phosphorylation of MBP and DYRKtide was measured in
triplicate as incorporation of 32P. Background values from the GFP
control samples were subtracted and activities were normalised to
the amount of kinase in the reaction as determined by GFP
immunoreactivity. Column diagrams illustrate catalytic activities
relative to HIPK2 (WT). The results were replicated in independent
experiments, except for a missing value of HIPK1.
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ylation status of the activation loop tyrosine in HIPK1,
HIPK2 and HIPK3 (Figure 3B,C). This result suggests that
these phosphotyrosines are not subject to turnover by
vanadate-sensitive tyrosine phosphatase activity under
these conditions, which argues against a regulatory role of
the activation loop tyrosine in the HIPKs. We can
however not exclude that changes in the phosphorylation
can take place under other circumstances, as reported for
HIPK2 [35,36].
Reduced catalytic activity of the HIPK Tyr→Phe mutants
The phosphotyrosines in HIPK1Y352F, HIPK2Y361F and
HIPK3Y359F result from autophosphorylation and thus
show that these Tyr→Phe mutants possess catalytic ac-
tivity. Hence, the catalytic domains of these kinases can
adopt an active conformation without tyrosine auto-
phosphorylation in the activation loop. Therefore, we
performed in vitro kinase assays to assess the Ser/Thr
kinase activities of the Tyr→Phe mutants towards ex-
ogenous substrates. First, we used recombinant p27Kip1
as a substrate, because this CDK inhibitor had been
shown to be a substrate of HIPK2 [40]. These assays
showed that all HIPKs are capable of phosphorylating
Ser10 in p27Kip1 in vitro (Figure 4A). Thus, the sequence
similarity of the catalytic domains of HIPK1-4 translates
into shared substrate recognition properties. Mutation of
the activation loop tyrosine strongly reduced the activity
of all HIPKs, supporting the hypothesis that this group
of kinases, like the DYRK family, depends on tyrosine
autophosphorylation for obtaining full catalytic activity.
As tyrosine autophosphorylation of HIPK2 has been
shown to control affinity for its substrates [28], we con-
ducted further kinase assays with two other substrates.
Myelin basic protein (MBP) was used as an established
in vitro substrate protein of HIPK2 [7], and we also
employed a peptide originally developed as a substrate
for DYRK1A [38]. Both substrates were phosphorylated
by all HIPKs, as detected by incorporation of 32P-
labelled phosphate (Figure 4B,C). Wild type HIPK4 was
the most active kinase, which may be explained by the
absence the C-terminal autoinhibitory domain that is
found in the other HIPKs. The Tyr→Phe mutants of all
HIPKs showed markedly reduced catalytic towards both
substrates. The larger differences between the wild type
and mutant enzymes probably reflect the superior prop-
erties of the radiometric assay, which provides a more
direct and accurate measurement of catalytic activities
[41]. Nonetheless, the Tyr→Phe mutants are enzymati-
cally active, consistent with previous reports that HIP-
K2Y361F has reduced but detectable activity towards
different substrates [28,29]. It must be noted that full ac-
tivity of HIPK2 also depends on the autophosphorylation
of a serine residue in the activation loop [28]. This serine
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teresting to study the role of this phosphorylation in the
regulation of all members of these kinase families.
Activation loop phosphorylation influences the
intracellular localisation of HIPKs
Elimination of the activation loop tyrosine has been re-
ported to alter the subcellular distribution of HIPK2,
suggesting that tyrosine autophosphorylation plays a
regulatory role in nuclear import or export of HIPK2
[28,29]. To reveal whether this effect was also present in
other HIPKs, we compared the subcellular distribution
of wild-type and mutant GFP-tagged HIPKs. COS-7 cells
were chosen for this analysis because their large, flat cel-
lular shape facilitates microscopic analysis.
As expected, most COS7 cells expressing wild type
HIPK2 showed a dotted distribution in the nucleus, with
about 12.5% of the cells also exhibiting cytoplasmic GFP
fluorescence (Figure 5B). A significantly larger percent-
age of HIPK2Y361F expressing cells displayed GFP fluor-
escence in the cytoplasm, and in some cells HIPK2Y361F
was largely excluded from the nucleus (lower panel of
Figure 5B, Additional file 1: Figure S3B). This effect of
the Tyr→Phe mutation basically reproduces previous
observations in U2OS cells reported by Siepi et al. [29].
By co-localisation studies, these authors have tentatively
identified the perinuclear structures in which GFP-
HIPK2Y361F accumulates as aggresomes. Importantly,
however, the majority of cells still contained nuclear
HIPK2Y361F, clearly indicating that autophosphorylation
of Tyr361 is not essential for nuclear import. The local-
isation of the kinase-deficient mutant HIPK2D324N did
not differ from that of wild type HIPK2. This is in con-
trast to previous observations that the catalytically in-
active mutants HIPK2-K221A and K221R lose the
localization in nuclear speckles [1,27]. This difference
may be due to the use of different point mutants, since
the mutation of K221 interferes with the binding of
ATP. Such mutants can be functionally distinct from
mutants that maintain the integrity of the ATP binding
site [42]. The use of different cell lines and levels of
overexpression may also have contributed to the ob-
served difference.
As shown in Figure 5A, wild type HIPK1 was also pre-
dominantly found in punctate nuclear structures, al-
though the percentage of cells with extranuclear staining
was higher than for HIPK2. Interestingly, HIPK1Y352F
showed essentially the same pattern of distribution as
HIPK2Y361F, with about 38% of cells displaying both nu-
clear and cytoplasmic fluorescence and about 9% nuclear
exclusion of HIPK1Y352F. Again, the kinase-deficient
HIPK1D315N mutant behaved like the wild type protein.
Hence, mislocalisation of the HIPK1 and HIPK2
Tyr→Phe mutants is not due to reduced catalyticactivity but must be considered a gain-of-function effect
(Figure 5A, Additional file 1: Figure S3A). One distinct-
ive feature of the Tyr→Phe mutants of HIPK1 and
HIPK2 is their altered residue specificity, with a reduced
Ser/Thr kinase activity (Figure 4) and enhanced tyrosine
kinase activity (Figure 3). Considering that tyrosine auto-
phosphorylation in the activation loop stabilises the ac-
tive conformation of the catalytic domain in CMGC
kinases [34], the more flexible structure of the Tyr→Phe
mutants allows for off-target tyrosine autophosphoryl-
ation. These phosphotyrosines may then interfere with
protein-protein interactions required for nuclear import.
In spite of the conserved domain structure and the
close sequence similarity with HIPK1 and HIPK2, HIPK3
showed a distinct pattern of distribution in COS7 cells
(Figure 5C). HIPK3 was almost exclusively detected in
the nucleus, and only very few cells with a weak cytoplas-
mic GFP signal were identified. About one quarter of the
cells lacked the typical punctate arrangement of nuclear
GFP fluorescence but displayed largely homogeneous nu-
clear staining. In contrast to HIPK1 and HIPK2, the
Y359F mutation of HIPK3 did not cause a significant cyto-
plasmic redistribution of the kinase (Figure 5C, Additional
file 1: Figure S3C). Interestingly, the absence of aggre-
somes in HIPK3Y359F-transfected cells correlates with the
observation that this mutant did not contain phosphotyro-
sine under basal conditions (Figure 3C). However, HIP-
K3Y359F markedly increased the percentage of cells with
homogeneous nuclear fluorescence. This effect was even
more pronounced in the catalytically inactive HIPK3D322N.
Thus, the association of HIPK3 with an as yet undefined
subnuclear speckle-like compartment depends on the
catalytic activity of the kinase.
In accordance with previous results [4], HIPK4 was ex-
cluded from the nucleus and was homogeneously distrib-
uted in the cytoplasm in most cells (Figure 5D). Very few
cells showed a punctate distribution throughout the cyto-
plasm. HIPK4Y175F and HIPK4D136N did not significantly
differ from the wild type protein in terms of subcellu-
lar appearance (Additional file 1: Figure S3D). The dif-
ferent behaviour of HIPK4 compared to HIPK1-3
correlates with the divergent domain structure and the
absence of a canonical nuclear localisation signal
(Additional file 1: Figure S3E).
Conclusions
DYRKs have become paradigm examples for their activa-
tion mechanism by cis-autophosphorylation of a tyrosine
residue in the activation-loop. Here we show that all
HIPKs also classify as dual specificity kinases that autop-
hosphorylate on tyrosine residues and depend on the ac-
tivation loop tyrosine for attaining full catalytic activity.
The biochemical and structural similarity of the HIPK




Figure 5 (See legend on next page.)
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Figure 5 Subcellular distribution of HIPK mutants. COS-7 cells were transfected with expression vectors for GFP-HIPK1 (A), GFP-HIPK2 (B),
GFP-HIPK3 (C) or GFP-HIPK4 (D). The cellular localisation of the HIPK constructs was evaluated by imaging GFP autofluorescence in relation to
bisbenzimide-stained nuclei. For each kinase, cells were classified into 3 major patterns that are illustrated by representative images and icons. The cells
shown were transfected with (top to bottom) HIPK1 WT, DN, YF; HIPK2 WT, WT, YF; HIPK3 WT, WT, DN and HIPK4 DN, DN. A series of images of the
different patterns for each kinase and its mutants is provided in the additional material (Additional file 1: Figure S3). Here the graphs show the
percentages of cells classified into the indicated patterns (means ± SD, n = 3). In each of 3 experiments, at least 90 cells were evaluated for all HIPK
constructs. Scale bars, 10 μm.
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tral feature of CMGC group kinases [30]. Consistently,
tyrosine kinase activity is an intrinsic property of the
catalytic domain of HIPK2 and does not depend on the
cellular context or the presence of the other domains
[29,34]. HIPK1-3 also resemble DYRK1A in being cap-
able to autophosphorylate as mature kinases tyrosines
other than that in the activation loop. Furthermore, our
observation that all HIPKs phosphorylate CDK inhibitor
p27Kip1 on Ser10 highlights the similarity of target rec-
ognition by HIPKs with DYRK1A and DYRK1B [43].
Phosphorylation on Ser10 reduces the proteasomal deg-
radation of p27Kip1 and may play a role in the antiapop-
totic functions of HIPKs [44].
In contrast to these common properties, HIPKs differ
strikingly in the regulatory role of the activation loop
tyrosine in subcellular targeting. The increased cytoplas-
mic localisation of HIPK1Y352F and HIPK2Y361F was not
found in the respective mutants of HIPK3 (Figure 5C) or
DYRK1A [29]. Interestingly, overexpression of the onco-
genic tyrosine kinase Src has recently been reported to
enhance tyrosine phosphorylation of HIPK2 and redis-
tribute the kinase to the cytoplasm [36]. Further studies
will be necessary to understand how tyrosine phosphor-
ylation affects the tumor-suppressive function of HIPK1
and HIPK2 in human cancers and to reveal the physio-
logical or pathophysiological relevance of tyrosine auto-
phosphorylation in the regulation of the other member
of the HIPK family.Table 1 List of GFP-HIPK expression clones





GFP-mHIPK1 NM_010432.2 O88904 [26]
GFP-hHIPK2 NM_001113239 Q9H2X6 [8]
GFP-rHIPK3 NM_031787 O88850 [22]
GFP-hHIPK4 NM_144685 Q8NE63 –Material and methods
Antibodies
The following antibodies were used: mouse monoclonal
antibodies against phosphotyrosine (PY99, sc-7020, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and p27Kip1
(BD Transduction laboratories, Heidelberg, Germany),
rabbit monoclonal antibodies specific for pS10-p27Kip1
(#ab62364, Abcam, Cambridge, UK) or pTyr361-HIPK2
(#PA5-13045, Thermo Scientific, Rockford, IL, USA) and
polyclonal goat antibody against green fluorescent pro-
tein (GFP, Rockland Immunochemicals Inc., 600-101-
215, Gilbertsville, PA, USA). A rat monoclonal HIPK2
antibody was kindly provided by M. Lienhardt Schmitz
(Justus-Liebig-University, Giessen, Germany).Plasmids
The vector plasmid pEGFP-C1 (Clontech Laboratories,
Mountain View, CA) was used for mammalian expres-
sion of HIPK fusion proteins with an N-terminal GFP
tag. Expression plasmids for GFP-HIPK1, GFP-HIPK2
and FLAG-HIPK2 were kindly provided by Cheol Yong
Choi (Sungkyunkwan University, Suwon, Korea) and M.
Lienhardt Schmitz (Table 1). The HIPK2 clones differ
from the human reference sequence in the Uniprot data-
base in two amino acid residues (H233R, F378S). Rat
HIPK3 cDNA was cut from pFLAG-CMV2-rHIPK3 (gift
of Jorma Palvimo, University of Eastern Finland, Kuopio,
Finland) with EcoRI and subcloned into pEGFP-C1. This
cDNA differed by one mismatch (A963V) from the Uni-
prot reference sequence. HIPK4 was PCR amplified
using a human cDNA clone (MGC:26964, Openbiosys-
tems, Huntsville, AL) as template and ligated into
pEGFP-C1 using N-terminal BglII and C-terminal EcoRI
sites. Correctness of PCR and cloning was verified by
DNA sequencing. Point mutants were created using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA, USA) and verified by DNA sequencing.
The designation of point mutants refers to the number-
ing of the reference proteins listed in Table 1 that are
defined as canonical sequence variants in the Uniprot
database (www.uniprot.org). Since two possible start co-
dons exist in HIPK2, the activation loop tyrosine in
HIPK2 has been numbered as Tyr354 in other reports
[28,29].
Cell culture and immunoprecipitation of GFP fusion
proteins
HeLa cells were cultivated on 100-mm plates in DMEM
(Dulbecco’s modified eagle medium) containing 10%
FCS (fetal calf serum) at 37°C and 5% CO2. Cells were
transfected with expression vectors for HIPK fusion
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Germany). If indicated, sodium orthovanadate (Na3VO4)
was added to the HeLa medium to a final concentration
of 100 μM 1 h before cell lysis. After 48 h, cells were
washed and lysed in 1 ml of native lysis buffer (50 mM
TrisHCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.5% NP-
40, supplemented with 1 mM Na3VO4, 1 mM phenyl-
methylsulfonylfluoride and 10 μg/ml each of aprotinin,
pepstatin and leupeptin). Samples were cleared off cell
debris by centrifugation and incubated with 15 μl GFP-
Trap® (ChromoTek, Martinsried, Germany) for 1 h at
4°C in and end-over-end rotator. GFP-Trap® beads were
collected using a magnetic rack and washed three times
with washing buffer (50 mM TrisHCl pH 7.5, 150 mM
NaCl, 2 mM EDTA, 0.1% NP-40). Bound proteins were
eluted in 10 μl Laemmli Sample Buffer supplemented
with 6 μg/100 μl dithiothreitol at 95°C and resolved by
SDS-PAGE.
Immunocomplex kinase assays
To measure the relative catalytic activities of the HIPK
Tyr→Phe mutants, GFP-Trap® immunoprecipitates were
equilibrated with kinase buffer (25 mM Hepes pH 7.0, 5
mM MgCl2, 0.5 mM dithiothreitol). Non-radioactive as-
says were performed in a total volume of 20 μL for 30
min at 30°C in the presence of 500 μM ATP and 20 ng/
μL of GST-p27, a fusion protein of glutathione S-
transferase and human p27Kip1. GST-p27 was produced
in Escherichia coli from the plasmid pGEX-5x-3-p27Kip1
(kindly provided by J. Vervoorts-Weber, Institute of
Biochemistry, RWTH Aachen University, Germany) and
purified by affinity adsorption to glutathione Sepharose.
Phosphorylation of Ser10 was detected by western blot
analysis, and relative catalytic activity was calculated by
normalising the p27(pSer10) signal to the amount of
kinase in the reaction, as determined by the intensity of
the GFP signal. Radiometric assays were performed in a
volume of 30 μL for 15 min at 30°C in the presence of
50 μM myelin basic protein from bovine brain (Sigma)
or 200 μM DYRKtide [39] and 10 μM of [γ-32P]ATP.
Phosphate incorporation was determined by the phos-
phocellulose method. Each data point was determined in
triplicate, and the linearity of the reactions was verified
by measuring incorporation of 32P after 30 min. Activ-
ities of wild type HIPK4 exceeded the linear range of the
assay and may be underestimated.
Western blotting
Samples were separated by SDS-PAGE using 8% acryl-
amide gels and blotted onto nitrocellulose membranes.
Membranes were blocked with 3% BSA in TBS-T buffer
(20 mM Tris–HCl pH 7.6, 137 mM NaCl, 0.2% Tween-
20) and incubated with the primary antibodies in a 1:1000
dilution at 4°C overnight. After washing, membranes wereincubated with secondary antibodies for 1 h. Chemilumin-
escence signals were detected with a LAS-3000 CCD im-
aging system and densitometrically quantitated using the
AIDA image analysis software (Raytest, Straubenhardt,
Germany).
Fluorescence microscopy
Glass coverslips (15 mm diameter) were transferred into
6-well plates and wells were filled with cell culture
medium. Subsequently, COS-7 cells were seeded and
grown for 24 h at 37°C in DMEM containing 10% FCS at
5% CO2 before transfection with GFP-HIPK expression
vectors using FuGENE HD. After incubation for additional
48 h, cells were carefully washed once with PBS buffer and
fixed using 1 ml 4% paraformaldehyde in PBS buffer for
10 minutes. Cells were then washed three times in 50 mM
Tris-HCl pH 7.6 and incubated with bisbenzimide (1:4000
dilution in 50 mM TrisHCl pH 7.6) for 10 minutes in dark-
ness in order to stain nuclear DNA. After that, coverslips
were mounted onto object slides using Immu-Mount™
(Thermo Fisher Scientific, Waltham, MA). Cells were then
analysed using a Axiovert 200 M inverted microscope
(Zeiss, Jena, Germany). Only cells with sufficient GFP and
bisbenzimide signal as well as vital appearance were
counted, aiming to count 100 cells per slide. Due to
inadequate transfection or fixation rates only >90 cells
could be evaluated in 2 cases. Images were processed using
Zeiss AxioVision 4.7 software. One-way ANOVA and
Tukey’s Multiple Comparison Test were applied to test sig-
nificant differences between mutants and wild type using
the GraphPad Prism 5 software (GraphPad Software Inc,
La Jolla, CA, USA).
Additional file
Additional file 1: Figure S1. Tyrosine autophosphorylation in different
FLAG-HIPK2 and GFP-HIPK2, HIPK2Y361F. Figure S2. Tyrosine
autophosphorylation of GFP-HIPK1-3 in the presence of
cycloheximide. Figures S3 and S4 contain additional images which
illustrate the different patterns of subcellular distribution for all HIPK
constructs (supporting information to Figure 5).
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